Why the study?
Is adjusted dose high intensity LMWH safe and effective for preventing thromboembolism in pregnant women with mechanical heart valves?
Is adjusted dose high intensity LMWH safe and effective for preventing thromboembolism in pregnant women with mechanical heart valves?
Adjusted dose high intensity LMWH is a viable therapeutic option for pregnant women with mechanical heart valves, provided anti-Xa levels are strictly maintained within the target range of 1.0-1.2 IU/mL.
Answers are grounded in this paper and cite their sources.
Cautious support for adjusted high-intensity LMWH with anti-Xa monitoring in pregnant mechanical valve patients; leaves open need for randomized confirmation.
The use of standard dose low molecular weight heparin (LMWH) to anticoagulate women with mechanical valves in pregnancy is associated with morbidity and mortality. We conducted a prospective audit of the use of adjusted dose high intensity LMWH in 12 pregnancies in 11 women with prosthetic heart valves. LMWH +/- low-dose aspirin was started at therapeutic-dose with monitoring of anti-Xa levels to achieve a target level of 1.0-1.2 IU/mL (0.8-1.2 in the first 3/12 pregnancies). This necessitated a mean increase in the dose of LMWH of 54.4% (SD+/-33.2) over initial dose. Eleven of 12 pregnancies resulted in live births, with one intrauterine fetal death at 37 weeks. One non-fatal valve thrombosis occurred at 26 weeks gestation associated with subtherapeutic anti-Xa levels. Three patients experienced major bleeding. This regime provides a therapeutic option for women with mechanical heart valves during pregnancy, provided anti-Xa levels are kept within the target range. These patients require close surveillance for bleeding and thrombotic complications within a multi-disciplinary setting.
No takes yet. Share an insight, caveat, or question.
Quinn et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: